Thumbnail Image
Publication

Therapy of solid tumors using probiotic Symbioflor-2: restraints and potential.

Kocijancic, Dino
; 
Felgner, Sebastian
; 
Frahm, Michael
; 
Komoll, Ronja-Melinda
; 
Iljazovic, Aida
; 
Pawar, Vinay
; ; 
Heise, Ulrike
; 
Zimmermann, Kurt
; 
Gunzer, Florian
... show 4 more
Citations
Altmetric:
Advisors
Editors
Other Contributors
Issue Date
2016-04-19
Submitted date
Show all metadata
Files
Thumbnail Image
allowed publisher's PDF
Adobe PDF, 9.23 MB
Thumbnail Image
supplemental information
Adobe PDF, 6.7 MB
Other Titles
Abstract
To date, virulent bacteria remain the basis of most bacteria mediated cancer therapies. For clinical application attenuation is required. However, this might result in a drastically lowered therapeutic capacity. Herein we argue that the E. coli probiotic Symbioflor-2, with a history of safe application may constitute a viable tumor therapeutic candidate. We demonstrate that Symbioflor-2 displays a highly specific tumor targeting ability as determined in murine CT26 and RenCa tumor models. The excellent specificity was ascribed to reduced levels of adverse colonization. A high safety standard was demonstrated in WT and Rag1-/- mice. Thus, Symbioflor-2 may represent an ideal tumor targeting delivery system for therapeutic molecules. Moreover, Symbioflor-2 was capable of inducing CT26 tumor clearance as result of an adjuvant effect on tumor specific CD8+ T cells analogous to the Salmonella variant SL7207. However, lower therapeutic efficacy against RenCa tumors suggested a generally reduced therapeutic potency for probiotics. Interestingly, concurrent depletion of Gr-1+ or Ly6G+ cells installed therapeutic efficacy equal to SL7207, thus highlighting the role of innate effector cells in restraining the anti-tumor effects of Symbioflor-2. Collectively, our findings argue for a strategy of safe strain application and a more sustainable use of bacteria as a delivery system for therapeutic molecules.
Citation
Therapy of solid tumors using probiotic Symbioflor-2: restraints and potential. 2016, 7 (16):22605-22 Oncotarget
Affiliation
Helmholtz Centre for infection research, Inhoffenstr. 7, 38124 Braunschweig, Germany.
Publisher
Journal
Oncotarget
URI
http://hdl.handle.net/10033/620605
DOI
10.18632/oncotarget.8027
PubMed ID
26981777
PubMed Central ID
Additional Links
Embedded video
Type
Article
Language
en
Description
Series/Report no.
ISSN
1949-2553
EISSN
ISBN
ISMN
Gov't Doc #
Sponsors
License
Collections
publications of the research group molecular Immunology (MOLI)